Financial News

<< Back
ViewRay Reports First Quarter 2019 Results

CLEVELAND, May 2, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the first quarter ended March 31, 2019.

(PRNewsfoto/ViewRay, Inc.)

First Quarter 2019 Highlights:

  • Received 7 new orders for MRIdian systems totaling $42.8 million, compared to 3 orders totaling $21.2 million in the first quarter of 2018.
  • Total revenue of $20.3 million, primarily from 3 revenue units and 1 system upgrade, compared to $26.2 million, primarily from 4 revenue units and 1 system upgrade, in the first quarter of 2018.
  • Total backlog increased to $237.5 million as of March 31, 2019, from $212.3 million as of December 31, 2018.
  • Cash and cash equivalents were $145.8 million as of March 31, 2019.

"Our first quarter results are a solid start to the year and reflect progress on our commercial, innovation, and clinical pipelines," said Scott Drake, President and CEO. "We are well-positioned to execute in 2019 and are focused on becoming the standard of care in radiation oncology."

First Quarter 2019 Financial Results:

Total revenue for the three months was $20.3 million, compared to $26.2 million for the same period last year. 

Total cost of revenue was $25.7 million, compared to $20.6 million for the same period last year. Total cost of revenue in the first quarter of 2019 was impacted by approximately $7.0 million of charges, primarily driven by higher than anticipated installation costs related to historical upgrade commitments. The $7.0 million includes $5.6 million of one-time charges and $1.4 million of expenses.

Total gross profit was $(5.4) million, compared to $5.6 million for the same period last year. 

Total operating expenses were $25.0 million, compared to $16.9 million for the same period last year.

Net loss was $33.4 million, or $0.34 per share, compared to $7.5 million, or $0.11 per share, for the same period last year. 

ViewRay had total cash and cash equivalents of $145.8 million at March 31, 2019.

Financial Guidance:

The Company is reiterating its financial guidance for the full year 2019. The Company anticipates 2019 total revenue to be in the range of $111 million to $124 million, and total cash usage to be in the range of $65-$75 million.

Conference Call and Webcast

ViewRay will hold a conference call to discuss results on Thursday, May 2, 2019 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 8616638. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.viewray.com.

After the live webcast, a replay of the webcast will remain available online on the investor relations page of ViewRay's corporate website, www.viewray.com, for 14 days following the call. In addition, a telephonic replay of the call will be available until May 9, 2019. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 8616638. 

About ViewRay

ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades and installations, ViewRay's financial guidance for the full year 2019 and ViewRay's conference call to discuss its first quarter results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, and the timing of delivery of ViewRay's products, the timing, results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019, as updated periodically by the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

 

 

VIEWRAY, INC.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)







Three Months Ended March 31,




2019



2018


Revenue:









Product


$

18,874



$

25,379


Service



1,291




692


Distribution rights



119




119


Total revenue



20,284




26,190


Cost of revenue:









Product



22,033




19,711


Service



3,615




909


Total cost of revenue



25,648




20,620


Gross margin



(5,364)




5,570


Operating expenses:









Research and development



5,031




3,770


Selling and marketing



4,885




3,246


General and administrative



15,109




9,846


Total operating expenses



25,025




16,862


Loss from operations



(30,389)




(11,292)


Interest income



220




2


Interest expense



(759)




(1,866)


Other (expense) income, net



(2,433)




8,342


Loss before provision for income taxes


$

(33,361)



$

(4,814)


Provision for income taxes







Net loss and comprehensive loss


$

(33,361)



$

(4,814)


Amortization of beneficial conversion feature related to Series A convertible preferred
stock


$



$

(2,728)


Net loss attributable to common stockholders, basic and diluted


$

(33,361)



$

(7,542)


Net loss per share, basic and diluted


$

(0.34)



$

(0.11)


Weighted-average common shares used to compute net loss per

   share attributable to common stockholders, basic and diluted



96,741,309




68,943,918


 

 

VIEWRAY, INC.

Consolidated Balance Sheets

(In thousands, except share and per share data)










March 31,

2019



December 31,

2018


ASSETS









Current assets:









Cash and cash equivalents


$

145,797



$

167,432


Accounts receivable



27,432




36,867


Inventory



65,140




49,462


Deposits on purchased inventory



7,642




8,142


Deferred cost of revenue



4,342




9,736


Prepaid expenses and other current assets



9,060




6,045


Total current assets



259,413




277,684


Property and equipment, net



15,279




13,958


Restricted cash



1,382




1,933


Right-of-use assets



12,055





Other assets



1,496




1,395


TOTAL ASSETS


$

289,625



$

294,970


LIABILITIES AND STOCKHOLDERS' EQUITY









Current liabilities:









Accounts payable


$

17,891



$

10,207


Accrued liabilities



16,207




9,983


Customer deposits



14,905




19,968


Operating lease liability, current



1,284





Deferred revenue, current



10,287




13,731


Total current liabilities



60,574




53,889


Deferred revenue, net of current portion



5,507




5,744


Long-term debt



55,402




55,364


Warrant liabilities



14,872




11,844


Operating lease liability, noncurrent



11,491





Other long-term liabilities



303




820


TOTAL LIABILITIES



148,149




127,661


Commitments and contingencies









Stockholders' equity:









Convertible preferred stock, par value of $0.01 per share; 10,000,000 shares authorized 
     at March 31, 2019 and December 31, 2018; no shares issued and outstanding
 
     at March 31, 2019 and December 31, 2018







Common stock, par value of $0.01 per share; 300,000,000 shares authorized at
     March 31, 2019 and December 31, 2018; 96,933,098 and 96,332,023 shares
     issued and outstanding at March 31, 2019 and December 31, 2018



959




952


Additional paid-in capital



572,855




565,334


Accumulated deficit



(432,338)




(398,977)


TOTAL STOCKHOLDERS' EQUITY



141,476




167,309


TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY


$

289,625



$

294,970


 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/viewray-reports-first-quarter-2019-results-300841983.html

SOURCE ViewRay, Inc.

Investor Relations: Michaella Gallina, Sr. Director, Investor Relations and Communications, ViewRay, Inc., 1-844-MRIdian (674-3426), Email: investors@viewray.com; Media Enquiries: Karen Hackstaff, Vice President, Strategy and Branding, ViewRay, Inc., Phone: +1 408-242-2994, Email: media@viewray.com

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449
Website: www.amstock.com
Email: info@amstock.com

In Need of Customer Support? Contact

  Language Select